Pacific Journal of Oncology & Immunotherapy
https://scienceget.org/index.php/pjoi
Vol. 2, No. 1, 2025
eISSN: 3067-8110
EDITORIAL
DOI: https://doi.org/10.70818/pjoi.2025.v02i01.061

Immunotherapy in Oncology: Bridging Science and Clinical Practice

Aung Naing*
* *Professor, Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA*

The landscape of cancer treatment has drastically evolved over the past few decades, thanks to advancements in immunotherapy. Traditionally, oncology treatments like surgery, chemotherapy, and radiation were the primary methods used to combat cancer. While these treatments remain essential, their limitations in efficacy and side effects have driven the exploration of immunotherapy, which seeks to empower the body's immune system to recognize and destroy cancer cells. Immunotherapy represents an innovative paradigm in cancer care, aiming to bridge scientific discoveries with clinical practice by harnessing the body's natural defenses. The clinical success of immunotherapy has been particularly notable in cancers that have previously had poor prognoses, including melanoma, non-small cell lung cancer (NSCLC), and metastatic bladder cancer. These therapies offer a new way of approaching cancer treatment, particularly through immune checkpoint inhibitors like pembrolizumab (Keytruda) and nivolumab (Opdivo), which have transformed the therapeutic options available for advanced cancer patients. However, the integration of immunotherapy into routine clinical practice is not without challenges. Issues such as high costs, treatment-related side effects, and the need for personalized approaches are complicating its widespread adoption. This editorial explores the current state of immunotherapy in oncology, delves into its scientific foundations, examines clinical applications, and looks at future directions in this rapidly evolving field.

Keywords: Cancer Treatment, Oncology, Immunotherapy, Tumor Microenvironment.

∗**Corresponding author**: Aung Naing

Received: March 15, 2025 | **Accepted:** May 18, 2025 | **Published:** June 01, 2025

At its core, immunotherapy works by exploiting the body's immune system to target and destroy cancer cells. The immune system, which comprises organs, cells, and molecules that protect the body from harmful invaders, normally operates with a balance between activation and inhibition to avoid attacking the body's own healthy cells. In the context of cancer, however, tumor cells often evade immune detection by exploiting various immune checkpoints and mechanisms that suppress immune activity. One of the key discoveries in cancer immunotherapy is the role of immune checkpoint proteins, particularly PD-1 (programmed cell death protein 1) and CTLA-4 (cytotoxic T-lymphocyte antigen 4), in dampening the immune response. Tumor cells often express ligands that bind to PD-1 and CTLA-4, thereby suppressing T-cell activation and allowing cancer cells to proliferate unchecked [1]. The development of immune checkpoint inhibitors aims to block these interactions, thereby "releasing the brakes" on the immune system and enhancing the body's ability to detect and eliminate cancer cells. Drugs like nivolumab and pembrolizumab have proven effective by targeting PD-1, while ipilimumab targets CTLA-4, with some therapies combining both approaches to maximize therapeutic efficacy [2, 3]. In addition to immune checkpoint inhibitors, other immunotherapy modalities such as monoclonal

antibodies, cancer vaccines, and adoptive T-cell therapies are being explored and refined. These therapies represent the growing understanding of how cancer cells interact with the immune system, enabling clinicians to develop more targeted and effective treatments.

Immunotherapy has already proven its worth in several cancer types, demonstrating substantial improvements in survival rates and quality of life for patients. The most significant breakthroughs have been in cancers that previously had limited therapeutic options, such as melanoma, NSCLC, and bladder cancer. These successes underscore the potential of immunotherapy to alter the treatment paradigm for cancer. In melanoma, the introduction of immune checkpoint inhibitors has led to remarkable improvements. Ipilimumab, an anti-CTLA-4 antibody, was the first immune checkpoint inhibitor approved for melanoma treatment, and its success was further amplified when combined with nivolumab (anti-PD-1) in clinical trials, showing significantly improved overall survival rates [4]. In patients with advanced or metastatic melanoma, this combination therapy has produced durable responses, with some patients remaining in remission for years. Non-small cell lung cancer (NSCLC) has also seen transformative outcomes with immunotherapy. Traditionally, chemotherapy was the cornerstone of treatment for NSCLC, but immunotherapies like pembrolizumab have shown superior survival benefits, particularly in patients whose tumors express the PD-L1 protein. Pembrolizumab has now become a standard treatment for advanced NSCLC, significantly improving survival compared to chemotherapy alone, especially in cases where the tumor is resistant to other treatments. Bladder cancer has long been a challenging cancer to treat, but atezolizumab and durvalumab, which inhibit PD-L1, have been shown to be effective in the treatment of advanced urothelial carcinoma [5]. These therapies are now incorporated into first-line treatment regimens for metastatic bladder cancer, offering a life-extending option for patients who would otherwise have limited alternatives.

While immunotherapy holds tremendous promise, it is not without challenges that must be addressed to optimize its clinical application. Side Effects: Immunotherapy, unlike traditional chemotherapy or radiation, works by stimulating the immune system, which can lead to immune-related adverse events (irAEs). These include inflammation and damage to healthy organs like the skin, lungs, liver, and gastrointestinal tract. Managing irAEs is a delicate balancing act for clinicians. Although immunotherapy-related side effects are often less toxic than those caused by chemotherapy, they can still be severe and require careful monitoring and treatment [6, 7]. The emergence of immune-related endocrinopathies, such as thyroiditis and adrenalitis, presents another challenge in long-term patient care. Efficacy Limitations: Immunotherapy is not a panacea, and not all cancer patients respond to it. In fact, a significant number of patients experience little to no benefit from immunotherapy, often due to tumor heterogeneity—the presence of different cancer cell subpopulations within a single tumor [8]. Additionally, certain cancers, such as pancreatic cancer and glioblastoma, have proven resistant to immune checkpoint inhibitors. Understanding the mechanisms underlying these resistant responses is an ongoing area of research, with the aim of developing strategies to overcome these hurdles. Cost and Accessibility: The high cost of immunotherapy drugs remains a significant barrier to their widespread adoption. With therapies like nivolumab and pembrolizumab costing tens of thousands of dollars per treatment course, many patients, especially in low-income regions, are unable to access these life-saving drugs. Moreover, healthcare systems, even in high-income countries, are struggling to accommodate the increasing cost burden of immunotherapies [9]. Efforts to reduce drug prices, optimize treatment regimens, and improve cost-effectiveness are urgently needed to make immunotherapy more accessible to all patients.

The future of immunotherapy is rife with exciting possibilities. Ongoing research is not only focused on improving the current therapies but also on expanding the range of cancers that can be treated effectively with immunotherapy. Combination Therapies: Combining immunotherapy with other treatment modalities like chemotherapy, radiation, or targeted therapies is a promising approach to overcome resistance and enhance therapeutic efficacy. For instance, combining immune checkpoint inhibitors with chemotherapy has shown synergy in treating various cancers, including NSCLC and ovarian cancer. Researchers are also exploring how radiation therapy might enhance the effects of immunotherapy by inducing tumor cell death and increasing the release of tumor antigens, making them more visible to the immune system. Personalized Cancer Vaccines: Cancer vaccines are emerging as an exciting approach to immunotherapy. Personalized vaccines that

are tailored to a patient's specific tumor profile hold promise for stimulating a robust immune response. These vaccines aim to target tumor-specific antigens, allowing the immune system to distinguish between cancerous and healthy cells.

Neoantigen vaccines, which target mutations unique to the patient's tumor, are currently undergoing clinical trials, with early results showing promise [10]. CAR T-Cell Therapy: Chimeric Antigen Receptor (CAR) T-cell therapy is a form of adoptive cell therapy that involves modifying a patient's T-cells to express receptors targeting specific cancer antigens. This therapy has already shown success in hematologic cancers like leukemia and lymphoma, and researchers are exploring ways to extend CAR T-cell therapy to solid tumors [11, 12]. The major challenge with CAR T-cells in solid tumors is overcoming the immunosuppressive microenvironment, but promising developments in this area could revolutionize the treatment of cancers like breast and pancreatic cancer. Targeting the Tumor Microenvironment: The tumor microenvironment (TME) plays a crucial role in immune evasion. The TME is composed of various cells and molecules that can either support or inhibit tumor growth and immune response. New strategies aim to modulate the TME by targeting myeloid-derived suppressor cells (MDSCs) and regulatory T-cells (Tregs) that inhibit immune activity. Research is also focusing on reprogramming the TME to make it more receptive to immunotherapy [13].

REFERENCES

1. Zhou YJ, Li G, Wang J, Liu M, Wang Z, Song Y, Zhang X, Wang X. PD-L1: expression regulation. Blood Science. 2023 Apr 1;5(2):77-91.
2. Yang J, Zeng R, Zhou J, Luo L, Lyu M, Liu F, Sun X, Zhou L, Wang X, Bao Z, Chen W. Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study. Translational Lung Cancer Research. 2022 Jun;11(6):1038.
3. Kim S. Targeting Tumor Microenvironment Modulation for Improved Outcomes in Immunotherapy-Based Cancer Treatments. Pacific Journal of Oncology & Immunotherapy. 2024 Dec 31;1(1):4-12.
4. Serritella AV, Shenoy NK. Nivolumab plus ipilimumab vs nivolumab alone in advanced cancers other than melanoma: a meta-analysis. JAMA oncology. 2023 Oct 1;9(10):1441-6.
5. Iacovelli R, Ciccarese C, Brunelli M, Battelli N, Buttigliero C, Caserta C, Buti S, Santini D, Carella C, Galli L, Verri E. First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin. Annals of Oncology. 2022 Nov 1;33(11):1179-85.
6. Isawa T, Toi Y, Sugawara S, Taguri M, Toyoda S. Incidence, clinical characteristics, and predictors of cardiovascular immune-related adverse events associated with immune checkpoint inhibitors. The Oncologist. 2022 May 1;27(5):e410-9.
7. van der Burg SH. Evaluating the Effectiveness of Cancer Vaccines in Treating Metastatic Melanoma Using Immune Modulation. Pacific Journal of Oncology & Immunotherapy. 2024 Dec 31;1(1):22-30.
8. El-Sayes N, Vito A, Mossman K. Tumor heterogeneity: a great barrier in the age of cancer immunotherapy. Cancers. 2021 Feb 15;13(4):806.
9. Barrios C, de Lima Lopes G, Yusof MM, Rubagumya F, Rutkowski P, Sengar M. Barriers in access to oncology drugs—a global crisis. Nature Reviews Clinical Oncology. 2023 Jan;20(1):7-15.
10. Lin MJ, Svensson-Arvelund J, Lubitz GS, Marabelle A, Melero I, Brown BD, Brody JD. Cancer vaccines: the next immunotherapy frontier. Nature cancer. 2022 Aug;3(8):911-26.
11. Schreiber R. Exploring Novel Biomarkers for Predicting Response to Combination Immunotherapy and Chemotherapy in Lung Cancer. Pacific Journal of Oncology & Immunotherapy. 2024 Dec 31;1(1):13-21.
12. Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood cancer journal. 2021 Apr 6;11(4):69.
13. Li Q, Shi Z, Zhang F, Zeng W, Zhu D, Mei L. Symphony of nanomaterials and immunotherapy based on the cancer–immunity cycle. Acta Pharmaceutica Sinica B. 2022 Jan 1;12(1):107-34.